# Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation

> **NCT05149365** · PHASE3 · COMPLETED · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 190 (actual)

## Conditions studied

- Acute-graft-versus-host Disease
- Allogeneic Hematopoietic Stem Cell Transplantation

## Interventions

- **DRUG:** Sitagliptin + Standard Prophylaxis
- **DRUG:** Standard Prophylaxis

## Key facts

- **NCT ID:** NCT05149365
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-22
- **Primary completion:** 2023-09-24
- **Final completion:** 2025-06-16
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2026-02-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05149365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05149365, "Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05149365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*